NCT03970733View on ClinicalTrials.gov

Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis

PHASE2CompletedINTERVENTIONAL
Enrollment

246

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

April 7, 2020

Study Completion Date

March 28, 2022

Conditions
Lyme Borreliosis
Interventions
BIOLOGICAL

VLA15

a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate

BIOLOGICAL

Placebo

PBS (Phosphate Buffered Saline)

Trial Locations (5)

13760

Regional Clinical Research, Inc, Endwell

13901

United Medical Associates, Binghamton

14609

Rochester Clinical Research, Inc., Rochester

06460

Clinical Research Consulting, LLC, Milford

06905

Stamford Therapeutics Consortium, Stamford

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

Valneva Austria GmbH

INDUSTRY

lead

Pfizer

INDUSTRY